Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
| Autor: | Geeta Gulati, Kirsten Nielsen, Tanja Skyttä, þórdís Jóna Hrafnkelsdóttir, Jürgen Geisler, Torbjørn Omland, Alexander R. Lyon, Elham Hedayati, Suvi Tuohinen, Birgitte Vrou Offersen, Agneta Månsson Broberg |
|---|---|
| Přispěvatelé: | HUS Heart and Lung Center, Department of Medicine, Clinicum, Læknadeild (HÍ), Faculty of Medicine (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Geislameðferð Myocarditis Anthracycline Management of heart failure 3122 Cancers Antineoplastic Agents Breast Neoplasms Heart failure 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors Trastuzumab Physiology (medical) Internal medicine Brjóstakrabbamein medicine Humans Anthracyclines Heart Failure Cardiotoxicity business.industry Cardio-Oncology (P Ameri Section Editor) Disease Management Cancer medicine.disease 3. Good health Radiation therapy 030220 oncology & carcinogenesis 3121 General medicine internal medicine and other clinical medicine Emergency Medicine Hjartasjúkdómar Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Current Heart Failure Reports Broberg, A M, Geisler, J, Tuohinen, S, Skytta, T, Hrafnkelsdóttir, Þ J, Nielsen, K M, Hedayati, E, Omland, T, Offersen, B V, Lyon, A R & Gulati, G 2020, ' Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer ', Current Heart Failure Reports, vol. 17, no. 6, pp. 397-408 . https://doi.org/10.1007/s11897-020-00486-8 |
| ISSN: | 1546-9530 |
| Popis: | Publisher's version (útgefin grein) Purpose of Review: Long-term survival has increased significantly in breast cancer patients, and cardiovascular side effects are surpassing cancer-related mortality. We summarize risk factors, prevention strategies, detection, and management of cardiotoxicity, with focus on left ventricular dysfunction and heart failure, during breast cancer treatment. Recent Findings: Baseline treatment of cardiovascular risk factors is recommended. Anthracycline and trastuzumab treatment constitute a substantial risk of developing cardiotoxicity. There is growing evidence that this can be treated with beta blockers and angiotensin antagonists. Early detection of cardiotoxicity with cardiac imaging and circulating cardiovascular biomarkers is currently evaluated in clinical trials. Chest wall irradiation accelerates atherosclerotic processes and induces fibrosis. Immune checkpoint inhibitors require consideration for surveillance due to a small risk of severe myocarditis. Cyclin-dependent kinases4/6 inhibitors, cyclophosphamide, taxanes, tyrosine kinase inhibitors, and endocrine therapy have a lower-risk profile for cardiotoxicity. Summary: Preventive and management strategies to counteract cancer treatment–related left ventricular dysfunction or heart failure in breast cancer patients should include a comprehensive cardiovascular risk assessment and individual clinical evaluation. This should include both patient and treatment-related factors. Further clinical trials especially on early detection, cardioprevention, and management are urgently needed. Open Access funding provided by University of Oslo (incl Oslo University Hospital). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink